Hello,
I am a Medical Scientist in Molecular Pathology at Peter MacCallum Cancer Centre and would appreciate some clarification regarding the HGVS nomenclature of a MET exon 14 skipping variant at the RNA level.
Using our DNA NGS assay, we detected the variant NM_000245.4(MET):c.3028G>C, p.(Leu964_Asp1010del). On our RNA assay, the corresponding event was identified as MET exon 14 skipping. We have routinely described the RNA alteration for this variant as r.2888_3028del. However, when we recently entered the variant into Mutalyzer, the recommended nomenclature was r.2891_3031del. We understand that Mutalyzer has applied the HGVS 3′ rule; however, we are uncertain whether this rule should be applied in this context, given the exception described on the HGVS RNA nomenclature page:

And the exception noted on the HGVS deletion nomenclature page:

Could you please clarify which RNA-level description would be considered correct according to current HGVS recommendations?
Any guidance you can provide would be greatly appreciated.
Kind regards,
Hannah Masotti
Medical Scientist – Molecular Oncology
Molecular Pathology
Phone
+61 3 8559 5405 (laboratory enquiries)
Email Hannah....@petermac.org
Peter Mac acknowledges the traditional owners of the land of the Kulin Nation. We pay our respect to
Elders, past, present and emerging
![]()